ScreenerHero

TWST Twist Bioscience Corporation - Common Stock

NAS · US · Healthcare · Biotechnology · twistbioscience.com
196.85USD+4.33%Mkt Cap: 12.51B $P/E: —

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agricult…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap12.51B USD
Enterprise Value11.77B USD
Revenue (TTM)431.80M USD
Gross Profit191.00M USD
Net Income (TTM)-77.67M USD
Revenue/Share7.03 USD
Last Price196.85 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees979
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-251.02
PEG—
EV/EBITDA-102.12
EV/Revenue27.26
P/S28.97
P/B26.53
EPS (TTM)-2.23
EPS (Forward)-0.75
52W Range
23.3098% of range200.31
52W High200.31 USD
52W Low23.30 USD
Profitability
Gross Margin50.72%
Oper. Margin-30.65%
EBITDA Margin-26.70%
Profit Margin-20.63%
ROE-16.42%
ROA-12.10%
Growth
Revenue Growth23.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-47.63M USD
CapEx (TTM)28.00M USD
FCF Margin-15.01%
FCF Yield-0.52%
Net Debt-58.25M USD
Net Debt/EBITDA0.51
Balance Sheet
Debt/Equity0.16
Current Ratio2.67
Quick Ratio1.98
Book Value/Sh7.11 USD
Cash/Share2.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)120.83 USD
Upside (mean)-38.6%
Target Range36.00 USD – 212.00 USD
36.00-38.6% to mean212.00
# Analysts12
Ownership
Shares Out.66.30M
Float61.97M
Insiders0.76%
Institutions116.98%
Short Interest
Short Ratio7.7d
Short % Float23.79%
Short % Out.18.86%
Shares Short12.51M
Short (prev mo.)14.11M
Technical
SMA 50135.71 (+45.0%)
SMA 20077.06 (+155.4%)
Beta2.22
S&P 52W Chg14.58%
Avg Vol (30d)1.92M
Avg Vol (10d)2.72M
Technical Indicators
RSI (14)71.7
MACD18.4852
MACD Signal15.5674
MACD Hist.+2.9178
BB Upper208.16 USD
BB Middle154.48 USD
BB Lower100.80 USD
BB Width69.50%
ATR (14)11.90 USD
Vol Ratio (20d)0.99x